Atea Pharmaceuticals (AVIR) EBT (2019 - 2026)

Atea Pharmaceuticals' EBT history runs 8 years deep, the most recent figure standing at -$45.4 million for Q1 2026.

• In Q1 2026, EBT fell 33.23% year-over-year to -$45.4 million; the TTM figure through Mar 2026 stood at -$175.8 million (down 26.87% YoY), while the FY2025 annual figure was -$164.5 million, up 1.76% from the prior year.
• EBT for Q1 2026 stood at -$45.4 million, up from -$51.6 million in the prior quarter.
• The five-year high for EBT was -$11.9 million in Q3 2022, with the low at -$62.9 million in Q1 2024.
• The 5-year median for EBT is -$35.3 million (2023), against an average of -$37.2 million.
• Peak annual rise in EBT reached 46.14% in 2022, while the deepest fall reached 457.19% in 2022.
• Atea Pharmaceuticals' EBT stood at -$34.3 million in 2022, then dropped by 13.14% to -$38.8 million in 2023, then gained by 14.16% to -$33.3 million in 2024, then sank by 54.98% to -$51.6 million in 2025, then increased by 12.09% to -$45.4 million in 2026.
• Business Quant data shows AVIR's EBT at -$45.4 million in Q1 2026, -$51.6 million in Q4 2025, and -$41.9 million in Q3 2025.